PharmaCyte Biotech (PMCB) News Today $1.62 +0.01 (+0.31%) Closing price 01/31/2025 03:58 PM EasternExtended Trading$1.60 -0.02 (-1.23%) As of 01/31/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period MyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comPharmaCyte completes tender offer to purchase sharesJune 15, 2023 | msn.comPharmaCyte Biotech Announces Final Results of Tender OfferJune 15, 2023 | finance.yahoo.comLos Angeles Biotech NewsJune 14, 2023 | bizjournals.comPharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per ShareMay 11, 2023 | finance.yahoo.comBiotech ETFs’ Performance Deserves A LookApril 21, 2023 | nasdaq.com300 biotech and pharma CEOs including the head of Pfizer call for a reversal of the abortion pill banApril 12, 2023 | fortune.comA 45-year-old biotech CEO may have reduced his biological age by at least 5 years through a rigorous medical program that can cost up to $2 million a year, Bloomberg reportedFebruary 2, 2023 | msn.comPharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanFebruary 2, 2023 | finance.yahoo.comPharmaCyte to evaluate opportunities; CEO steps downOctober 7, 2022 | seekingalpha.comPharmaCyte Names Joshua Silverman Interim CEO As CEO Kenneth Waggoner Steps DownOctober 7, 2022 | markets.businessinsider.comPharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalAugust 15, 2022 | finance.yahoo.comIroquois Files Preliminary Consent Materials to Reconstitute Board of Directors at PharmaCyte Biotech, Inc.July 28, 2022 | finance.yahoo.comPharmaCyte Biotech Commences First Phase of Two-Phase Pig StudyJuly 21, 2022 | finance.yahoo.comIROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORSJuly 11, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022July 11, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap CellsJuly 5, 2022 | finance.yahoo.comIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETINGJune 23, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital's Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 17, 2022 | stockhouse.comPharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder ValueJune 15, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 2022 BIO International Convention in San DiegoJune 13, 2022 | finance.yahoo.comPharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder ValueJune 8, 2022 | finance.yahoo.comPharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for DiabetesApril 27, 2022 | finance.yahoo.comPharmaCyte Biotech Shares Reverse Course, Drop 8%April 19, 2022 | marketwatch.comPharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA RequirementsApril 19, 2022 | finance.yahoo.comPharmaCyte gets on with preparations for pancreatic cancer trial amid FDA clinical holdApril 13, 2022 | seekingalpha.comPharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical TrialApril 13, 2022 | finance.yahoo.comPharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of DirectorsApril 5, 2022 | finance.yahoo.comPharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product CandidateMarch 22, 2022 | finance.yahoo.comPharmaCyte Biotech (OTCMKTS:PMCB) Raised to Buy at Zacks Investment ResearchZacks Investment Research raised PharmaCyte Biotech from a "hold" rating to a "buy" rating and set a $2.50 price objective for the company in a research note on Saturday.March 19, 2022 | marketbeat.comPharmaCyte Biotech reports Q3 resultsMarch 18, 2022 | seekingalpha.comPharmaCyte Biotech Reports Third Quarter Financial Results and Operational HighlightsMarch 16, 2022 | finance.yahoo.comPharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of IntegrationFebruary 22, 2022 | finance.yahoo.comPharmaCyte Biotech (OTCMKTS:PMCB) Downgraded by Zacks Investment ResearchZacks Investment Research lowered shares of PharmaCyte Biotech from a "buy" rating to a "hold" rating in a research report on Wednesday.February 16, 2022 | marketbeat.comPharmaCyte Biotech Updates Status of Investigational New Drug Application to FDAFebruary 14, 2022 | finance.yahoo.comPharmaCyte Biotech (OTCMKTS:PMCB) Upgraded to "Buy" by Zacks Investment ResearchZacks Investment Research upgraded PharmaCyte Biotech from a "hold" rating to a "buy" rating and set a $2.75 price target on the stock in a research report on Tuesday.January 11, 2022 | marketbeat.comPharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated CellsJanuary 4, 2022 | finance.yahoo.comPharmaCyte Biotech Reports Q2 2021 Cash On Hand $87MDecember 16, 2021 | benzinga.comPharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational HighlightsDecember 15, 2021 | finance.yahoo.com5 Penny Stocks With Long-Term Growth CatalystsOctober 5, 2021 | insidermonkey.comPharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNASeptember 27, 2021 | finance.yahoo.comPharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility TestsSeptember 21, 2021 | finance.yahoo.comThinking about buying stock in Camber Energy, Farmmi, Offerpad Solutions, Pharmacyte Biotech, or Barrick Gold?September 16, 2021 | benzinga.comPharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDASeptember 16, 2021 | finance.yahoo.com Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCB Media Mentions By Week PMCB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PMCB News Sentiment▼1.440.69▲Average Medical News Sentiment PMCB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PMCB Articles This Week▼20▲PMCB Articles Average Week Get PharmaCyte Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PMCB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DYAI News Today ATRA News Today TPST News Today ITRM News Today VYNE News Today RAPT News Today BRNS News Today ATNM News Today CASI News Today QTTB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PMCB) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredThe #1 Stock for Trump’s First 100 DaysLegendary investor Louis Navellier believes this is just the beginning of Trump's 100-day melt-up. You shou...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PharmaCyte Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PharmaCyte Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
